GS-9820 (formerly CAL-120) is an oral, small molecule delta selective Phosphatidylinositol 3-kinases (PI3 kinase) inhibitor, a first in class compound, with greater than 200-fold selectivity in cell-based assays for the delta isoform as compared to other class isoforms. GS-9820 is designed to induce cancer cell death and inhibit signaling pathways associated with cancer cell dependence on the tumor microenvironment. GS-9820 is on the phase I of clinical trial, where has to be determined the appropriate dosing regimen of drug in subjects with lymphoid malignancies.

Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity (IC50=1.2 nM). It was in clinical development for the treatment of the solid tumors but later was discontinued.

RO-5028442 (RG7713) is a potent and highly selective arginine vasopressin receptor 1A (V1a) antagonist. This compound has been studied for use in autistic spectrum disorder. A phase I study in adult male high-functioning autistic patients has been completed in 2016 and showed that blockade of the V1a receptor may improve social communication in adults with high-functioning ASD. Eye-tracking results showed an increase in biological motion orienting preference. Only mild or moderate adverse events were reported.